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Abstract
Recent reports have revealed myelodysplastic syndromes (MDS) to arise from cancer stem
cells phenotypically similar to physiological hematopoietic stem cells. Myelodysplastic
hematopoiesis maintains a hierarchical organization, but the proportion of several hemato-
poietic compartments is skewed and multiple surface markers are aberrantly expressed.
These aberrant antigen expression patterns hold diagnostic and therapeutic promise. How-
ever, eradication of MDS requires targeting of early myelodysplasia propagating stem cells.
This warrants an exact assessment of the differentiation stage at which aberrant expression
occurs in transformed hematopoiesis. Here, we report results on the prospective and exten-
sive dissection of the hematopoietic hierarchy in 20 patients with either low-risk MDS or
MDS with excess blasts and compare it to hematopoiesis in patients with non-malignancy-
associated cytopenia or B cell lymphoma without bone marrow infiltration. We found
patients with MDS with excess blasts to exhibit characteristic expansions of specific imma-
ture progenitor compartments. We also identified the aberrant expression of several mark-
ers including ALDH, CLL-1, CD44, and CD47 to be specific features of hematopoiesis in
MDS with excess blasts. We show that amongst these, aberrant CLL-1 expression mani-
fested at the early uncommitted hematopoietic stem cell level, suggesting a potential role as
a therapeutic target.
Introduction
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal hematopoietic
disorders leading to ineffective hematopoiesis. Recent reports have revealed the existence of
MDS propagating stem cells [1–5]. While the hematopoietic hierarchy is conserved in MDS,
hematopoietic stem and progenitor cell (HSPC) populations were shown to be skewed [2,4,5].
Cancer stem cells are suggested not only to initiate malignancies but also to constitute a
pool of quiescent cells that can hardly be eliminated by conventional therapy [3]. Thus, the
elimination of cancer stem cells is deemed to be both essential and sufficient to eradicate
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cancer. The identification of aberrant surface markers on cancer cells has fueled considerable
efforts to develop specific antineoplastic therapies. However, in order to target cancer propa-
gating stem cells, a precise assessment of the timing of aberrant expression of individual mark-
ers during malignant hematopoiesis is required. Many aberrant cell surface markers have been
identified in MDS (reviewed in [6]), including recent work reporting the expression of IL-1
receptor accessory protein (IL1RAP) and CD99 on myelodysplastic stem cells [7,8]. In the case
of other putative targets, the expression has not been tracked to the exact differentiation stage
within the progenitor cell compartment [9]. In addition, several markers known to be aber-
rantly expressed in other myeloid malignancies such as acute myeloid leukemia (AML), have
so far not been assessed in MDS [10,11].
Here, we present the prospective and extensive examination of the hematopoietic hierarchy
in 20 patients with MDS in comparison with patients exhibiting either non malignancy-associ-
ated cytopenia or B-Non-Hodgkin-Lymphoma (B-NHL) without bone marrow infiltration.
Building upon recently characterized approaches to delineate all major immature hematopoi-
etic compartments, we identified specific alterations in the composition of HSPC compart-
ments in MDS with excess blasts and showed the aberrant expression of several markers
including aldehyde dehydrogenase (ALDH), C-type lectin-like molecule-1 (CLL-1, also
known as CLEC12A), CD13/CD33, CD44 and CD47 in a differentiation-stage specific man-
ner. This establishes CLL-1 as a potential therapeutic and ALDH as a a potential diagnostic tar-
get in MDS with excess blasts.
Patients and methods
Patient samples
Bone marrow samples from 69 patients were collected after informed consent, in accor-
dance with the Declaration of Helsinki and after approval by Charite´’s ethics committee.
The study did not involve the use of donated tissue from any vulnerable populations.
Twenty-one patients were excluded from analysis due to lack of a definitive diagnosis
(n = 6) or due to infiltration of the bone marrow with a non-MDS malignancy (n = 15). A
diagnosis of MDS was made according to the WHO 2016 classification and based on mor-
phology (cytomorphology of bone marrow aspirate and bone marrow biopsy), flow cytome-
try, and cytogenetics. The group of patients with MDS included 12 cases without excess
blasts (< 5%; hereinafter referred to as “low-risk MDS”) as well as 8 cases of MDS with
excess blasts (one case of MDS-EB-1 with 5–9% blasts and seven cases of MDS-EB-2 with
10–19% blasts, respectively; hereinafter also referred to as “high-risk MDS”). Controls con-
sisted of patients with non-MDS related cytopenia (n = 17) and another group with newly
diagnosed B-NHL without prior treatment (n = 11). In both of these control groups, mor-
phologic assessment (bone marrow biopsy and bone marrow aspirate) and flow cytometry
were performed to rule out a malignant cause in patients with non-MDS related cytopenia,
and to exclude bone marrow infiltration in patients with newly diagnosed B-NHL. There
were no significant differences in the proportions of hematopoietic compartments between
these two control groups (data not shown). For comparisons with MDS patients, all control
cases were assessed together.
A total of 48 patients with a median age of 68 years (range: 22–100 years) were included in
the final analysis (ratio male:female: 0.65:0.35). There were no significant differences regarding
age and gender distribution between MDS groups (median age 70 years, range 33–100; ratio
male:female 0.6:0.4) and controls (median age 64 years, range 22–88; ratio male: female
0.68:0.32).
Phenotypic assessment of hematopoiesis in MDS
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Flow cytometry
Samples for flow cytometric analysis were processed within 48 hours after collection. Red
blood cells were lysed using commercial lysing buffer (Pharm Lyse, BD Biosciences) according
to the manufacturer’s instructions. Antibody stainings were performed for 20 minutes on ice.
Flow cytometric identification of uncommitted hematopoietic stem cells (HSC; SSC(lo)CD34+
CD10-CD38-CD90+), multipotent progenitor cells (MPP; SSC(lo)CD34+CD10-CD38-CD90-
CD45RA-), lymphoid-primed multipotent progenitor cells (LMPP; SSC(lo)CD34+CD10-
CD38-CD90-CD45RA+), common lymphoid progenitor cells (CLP; SSC(lo)CD34+CD10+),
common myeloid progenitor cells (CMP; SSC(lo)CD34+CD10-CD38+CD123(int)CD45RA-),
granulocyte macrophage progenitor cells (GMP; SSC(lo),CD34+CD10-CD38+CD123(int)
CD45RA+), and megakaryocyte erythroid progenitor cells (MEP; SSC(lo)CD34+CD10-CD38+
CD123-CD45RA-) was performed according to established protocols and as illustrated in Fig
1A and 1B [12–15]. Importantly, as a modification to published approaches we did not perform
exclusion of lineage-positive cells owing to a high probability of aberrant expression of lineage
markers on myelodysplastic progenitor cells [16–19]. Dead cells were excluded by 7-AAD stain-
ing (Beckman Coulter) and isotype controls were used where appropriate. For the analysis of
CD44/CD47 expression the geometric mean (mean fluorescence intensity, MFI) was used and
reported as log10, since aberrant expression of these markers occurs in a gradual rather than an
“on-off” fashion [20,21]. On average, 2237 CD34+ cells were acquired per sample (range, 155–
14703).
Staining panels included antibodies for CD45, CD34, CD10, CD38, CD45RA, and either
CD90 or CD123 to characterize the hematopoietic hierarchy as outlined above as well as one
antibody per test tube for the detection of aberrant antigen expression (CD44, CD47, CLL-1,
or combined CD13/CD33) (Table 1). Staining panels for the detection of ALDH included anti-
bodies for CD45, CD34, CD10, and CD38. Antibodies were obtained from Beckman Coulter
(anti-CD13 FITC-conjugated, clone SJ1D1; CD123-PC7, clone SSDCLY107D2; CD45RA-PE,
clone ALB11; CD38-PB, clone LS198-4-3; CD33-FITC, clone D3HL60.251; CD34-APC, clone
581; CD10-ECD, clone ALB1; CD44-FITC, clone J.173), and BD Biosciences (CD90-PC7,
clone 5E10; CD47-FITC, clone B6H12; CLL-1-FITC, clone 50C1). Isotype controls were from
Beckman Coulter. For evaluation of ALDH expression Aldefluor staining (Stemcell Technolo-
gies) was performed according to the manufacturer’s instructions.
Statistical analysis
To test for significant differences of continuous variables between multiple groups the non-
parametric Kruskal-Wallis rank sum test was employed. Post-hoc testing to compare individual
groups was performed using pairwise Wilcoxon rank-sum tests and p-values were false discov-
ery rate-adjusted. To test for significant differences in age between controls and patients with
MDS a two-tailed student’s t-test was employed. The Chi-squared test was employed to test for
differences in gender distribution between groups. All analyses were performed using R statisti-
cal software (The R Foundation for Statistical Computing). The level of significance was 0.05.
Results
Quantification of stem and progenitor cell subpopulations in MDS
We first set out to assess the hematopoietic hierarchy in MDS using a modified gating
approach without exclusion of lineage-positive cells as described in the methods section (Fig
1A–1B). As expected, patients with MDS-EB showed a significantly enlarged proportion of
Phenotypic assessment of hematopoiesis in MDS
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CD34+ cells, driven by non-lymphoid committed CD10- cells (Fig 1C). This expansion of
CD34+CD10- cells was due to an increase of both CD38- and CD38+ populations.
Fig 1. Dissection of all major hematopoietic stem and progenitor cell (HSPC) compartments in MDS reveals expansion of MPP,
LMPP, CMP, and GMP compartments in MDS with excess blasts (MDS-EB). (a) Schematic representation of major HSPC populations
identified by the employed gating strategy. (b) Representative example of gating hierarchy. (c) Proportions of HSPC compartments in
control versus MDS patients expressed as percent of viable bone marrow cells. White crossbars represent the median and boxplots hinges
represent the first and third quartiles. p<0.05, p<0.01; CLP, common lymphoid progenitor cells; CMP, common myeloid progenitor
cells; GMP, granulocyte macrophage progenitor cells; HSC, uncommitted hematopoietic stem cell; LMPP, lymphoid-primed multipotent
progenitor cells; MEP, megakaryocytic erythroid progenitor cells; MPP, multipotent progenitor cells.
https://doi.org/10.1371/journal.pone.0197823.g001
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Interestingly, the expansion of the more immature CD34+CD10-CD38- compartment was
driven by an increase of both the CD90-CD45RA- MPP and the CD90-CD45RA+ LMPP com-
partments rather than of uncommitted CD90+CD45RA- HSCs. In contrast, the assessment of
more mature CD34+CD10-CD38+ cells revealed an expansion of GMP in patients with
MDS-EB. We also assessed the abundance of these progenitor populations in relation to their
CD34+CD10-CD38+ parent population. Using this metric, we found the relative proportion
of MEPs (proportion MEPs/CD34+CD10-CD38+ cells) to be significantly reduced in both
patients with low-risk MDS and MDS-EB as compared to control patients (S1 Fig).
CLL-1 is upregulated on immature stem cells in MDS with excess blasts
We next set out to assess the expression of various markers at different differentiation stages
within the HSPC compartment. CLL-1 was expressed at particularly high levels in in various
HSPC compartments of MDS-EB patients, including HSCs, MPPs, LMPPs, CMPs, and MEPs
(Fig 2). This aberrant CLL-1 expression was also observed in the aggregate compartments of
CD34+ and CD34+CD10-CD38- cells, indicating that aberrant CLL-1 expression can be
detected using smaller antibody panels.
We next analyzed the expression of CD44 and CD47 in myelodysplastic HSPCs. In both
patients with low-risk MDS and patients with MDS-EB CD44 was upregulated on MEPs
(Fig 3A).
The assessment of CD47 showed aberrant overexpression in CMPs and MEPs of patients
with MDS-EB, which was also evident in the CD34+CD10-CD38+ parent compartment (Fig
3B). There was also upregulation of CD47 on HSC. However, this difference did not reach sta-
tistical significance (p = 0.07).
Low-risk MDS and MDS-EB show aberrant expression of CD13/CD33
We next assessed the combined expression of the myeloid markers CD13 and CD33. Aberrant
upregulation of CD13/CD33 was evident in MDS-EB patients in the progenitor compartments
of both CMPs and MEPs (Fig 4). Importantly, this aberrant upregulation was also evident in
patients with low-risk MDS. In MDS-EB patients these changes were reflected in the CD34+
and CD34+CD10- progenitor populations as a whole. In low-risk MDS patients, no significant
changes were observed in the CD34+ and CD34+CD10- populations, highlighting that more
careful phenotypic dissection of these aggregate compartments enhances detection sensitivity
in such patients.
Reduced ALDH expression in the CD34+CD10-CD38- compartment in
MDS with excess blasts
We next aimed to assess the expression of ALDH. Interestingly, in patients with MDS-EB
there was a significant reduction of ALDH-expressing cells in the CD34+CD10-CD38- com-
partment (Fig 5).
Table 1. Antibody panels used for flow cytometry analyses.
Panel PE ECD 7-AAD APC PB KrOr PC7 FITC
A CD45RA CD10 7-AAD CD34 CD38 CD45 CD90 One of the following: CD13/CD33, CD47, CD44, CLL-1
B CD45RA CD10 7-AAD CD34 CD38 CD45 CD123 One of the following: CD13/CD33, CD47, CD44, CLL-1
C CD45RA CD10 7-AAD CD34 CD38 CD45 - ALDH (Aldefluor)
Cells were analyzed using a Navios flow cytometer (Beckman Coulter). Kaluza software (Beckman Coulter) was employed to analyze flow cytometry data. Diagnoses of
patients were blinded during gating.
https://doi.org/10.1371/journal.pone.0197823.t001
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Discussion
Myelodysplastic syndromes have recently been established to be propagated by cancer stem
cells with the capacity of disease initiation, self-renewal, and resistance to antineoplastic ther-
apy [1–5]. A potentially curative therapeutic approach requires targeting this cancer stem cell
compartment, phenotypically resembling immature, uncommitted physiologic HSC [6]. Here,
we employed a modification of previously published gating strategies to assess the hematopoi-
etic architecture as well as the expression of aberrant antigens in 20 patients with MDS. This
gating strategy allowed for the detection of aberrant immunophenotypes at distinct differentia-
tion stages within the hematopoietic progenitor cell compartment and not only in CD34+ cells
as a whole.
Several studies have reported the aberrant expression of multiple antigens by cancer stem
cells in AML, including CLL-1, CD47, CD44, and ALDH [11,20–22]. Targeting CLL-1, CD47,
and CD44 showed promise in preclinical models of AML [21,23,24]. The expression of many
of these antigens has been assessed in MDS in less specifically defined cell compartments,
mostly in the CD34+CD38- compartment containing HSCs, MPPs, and LMPPs [2,22,25–27].
For CLL-1 we are able to show aberrant expression in HSCs of patients with MDS-EB. This
suggests that CLL-1 has disease eliminating potential as a therapeutic target. Whether this is
also the case for CD47 will have to be addressed in additional studies. In contrast, we show
that increased expression of CD44 on CD34+CD38- cells in MDS-EB [19] is caused by MPPs
and LMPPs but not HSC. This suggests that targeting CD44 might not be sufficient to eradi-
cate MDS propagating clones.
Fig 2. Aberrant CLL-1-expression in MDS with excess blasts manifests at the uncommitted hematopoietic stem
cell (HSC) stage and affects multiple progenitor cell compartments. White crossbars represent the median
expression and boxplots hinges represent the first and third quartiles. p<0.05, p<0.01, p<0.001; CLP, common
lymphoid progenitor cells; CMP, common myeloid progenitor cells; GMP, granulocyte macrophage progenitor cells;
LMPP, lymphoid-primed multipotent progenitor cells; MEP, megakaryocyte erythroid progenitor cells; MPP,
multipotent progenitor cells.
https://doi.org/10.1371/journal.pone.0197823.g002
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Fig 3. CD44 and CD47 are upregulated in specific hematopoietic compartments of patients with MDS with excess
blasts. Expression of CD44 (a) and CD47 (b) was assessed in hematopoietic stem and progenitor cell compartments of
control, low-risk and MDS-EB patients. White crossbars represent the median expression and boxplots hinges
represent the first and third quartiles. p<0.05, p<0.01, p<0.001; CLP, common lymphoid progenitor cells;
CMP, common myeloid progenitor cells; GMP, granulocyte macrophage progenitor cells; HSC, hematopoietic stem
cells; LMPP, lymphoid-primed multipotent progenitor cells; MEP, megakaryocyte erythroid progenitor cells; MPP,
multipotent progenitor cells.
https://doi.org/10.1371/journal.pone.0197823.g003
Phenotypic assessment of hematopoiesis in MDS
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Loss of ALDH expression has previously been found to be characteristic of leukemic stem cells
in AML but has not been assessed in MDS so far [11,28]. Here, we show that, analogous to AML,
patients with MDS-EB exhibit lower expression of ALDH in the CD34+CD38- compartment, fur-
ther underpinning the biological relation between the two diseases and providing an additional
Fig 4. Combined expression of CD13/CD33 in MDS is upregulated in common myeloid progenitor cells (CMP)
and megakaryocyte erythroid progenitor cells (MEP). The combined expression of CD13 and CD33 was assessed in
hematopoietic stem and progenitor cell compartments of control versus MDS patients. White crossbars represent the
median expression and boxplots hinges represent the first and third quantiles. p<0.05, p<0.01, p<0.001; CLP,
common lymphoid progenitor cells; GMP, granulocyte macrophage progenitor cells; HSC, hematopoietic stem cells;
LMPP, lymphoid-primed multipotent progenitor cells; MPP, multipotent progenitor cells.
https://doi.org/10.1371/journal.pone.0197823.g004
Fig 5. ALDH expression is diminished in CD38-negative hematopoietic progenitor cells in MDS with excess
blasts. The expression of ALDH was assessed in common lymphoid progenitor cells (CLP), and compartments of
CD34+, CD34+CD10-, CD34+CD38- and CD34+CD38+ cells. White crossbars represent the median expression and
boxplots hinges represent the first and third quartiles. p<0.05.
https://doi.org/10.1371/journal.pone.0197823.g005
Phenotypic assessment of hematopoiesis in MDS
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marker to identify myelodysplastic stem cells. Future studies will need to establish whether MDS
propagating cells are enriched in the ALDH-low compartment in analogy to AML.
Most aberrant markers are upregulated only in patients with MDS-EB, suggesting that they
are not useful for the diagnosis of low-risk MDS. In this study, we observed an upregulation of
the myeloid antigens CD13/CD33 on CMPs and MEPs of patients with both low-risk MDS
and MDS-EB, confirming this marker combination to be useful in the diagnosis of low-risk
MDS [18,29]. CD13 and CD33 have been suggested as a potential therapeutic target in MDS
[17–19]. Our data, while not allowing for the distinction between CD13 and CD33, suggest
that targeting either marker might not eradicate the more immature, disease propagating com-
partments. Surprisingly, while not statistically significant, we also observed variable degrees of
CD13/CD33 expression on CLPs of MDS-EB patients. Hypothetically, this can be explained by
myelodysplastic HSCs also giving rise to lymphoid progeny or by aberrant expression of CD10
on myeloid cells. More comprehensive phenotypic characterization of this compartment than
in this myeloid-focused study is warranted in future studies.
Certain caveats potentially complicate antigen targeting therapy in MDS. First, eradication
of the entire disease clone requires expression of the target on all cancer propagating stem
cells. However, in the case of CLL-1, a recent study showed that only a subset of MDS stem
cells aberrantly expresses this antigen, indicating that CLL-1 targeting might not completely
eradicate the MDS propagating compartment [25]. Second, in order to minimize toxicity, the
expression of the target antigen should ideally be restricted to malignant cells. This is not the
case for most antigens, whose expression can also be detected on more mature hematopoietic
cells (as in the case of CLL-1) or to a lower degree also on physiologic HSCs [2,22,26]. Deplet-
ing more mature physiologic hematopoietic cells while sparing physiologic HSCs as predicted
for CLL-1 targeting should pose less a problem, as evident in long-established therapies such
as the depletion of mature B cells in CD20+ B cell leukemia/lymphoma. In the case that the tar-
get antigen is also expressed on physiologic HSCs, differences in the expression levels might
provide for a therapeutic window.
Previous studies showing that myelodysplastic hematopoiesis maintains a hierarchical orga-
nization employed stringent exclusion of lineage-positive cells [2,4,5]. However, lineage mark-
ers have been demonstrated to be aberrantly expressed in MDS stem and progenitor
compartments [16–19]. Therefore, to address this concern, we here employed an alternative
gating approach without exclusion of lineage-positive cells. We found that patients with
MDS-EB exhibited expanded MPP and GMP compartments while the MEP compartment was
reduced in both low-risk MDS and MDS-EB relative to the CD34+CD10-CD38+ compart-
ment. Importantly, in patients with MDS-EB we also showed an expansion of the
CD90-CD45RA+ LMPP compartment, which is enriched for leukemic stem cells in AML and
has previously not specifically been assessed in MDS [12]. Of note, some of the antigens used
to define hematopoietic progenitor compartments including CD123 can also be aberrantly
expressed in MDS [17]. These findings as well as the approach regarding exclusion of lineage
+ cells are important factors potentially accounting for discrepancies between studies assessing
antigen expression in myelodysplastic hematopoiesis.
Certain study limitations need to be considered in the interpretation of our findings. First,
the sample size was relatively small, in particular in light of the heterogeneity of MDS. As such,
it is not possible to draw conclusions about phenotypic alterations in specific MDS subsets and
to reliably assess the generalizability of our findings. Most phenotypic alterations described in
this study were only detected in MDS-EB, with low-risk MDS often showing a trend with no
statistical significance. It is conceivable that our study was underpowered to reliably detect
alterations in these low-risk cases. Second, given their low abundance in the bone marrow, the
number of recorded events for certain bone marrow progenitor subpopulations was low.
Phenotypic assessment of hematopoiesis in MDS
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Therefore, we cannot definitely decide whether the relatively high variability in the expression
of several markers is due to the biological heterogeneity of MDS or due to a sampling bias
which might have occurred in such a small population. In light of these limitations future stud-
ies are required to confirm our findings in larger patient cohorts.
In summary, we identified particular differentiation stages of dysplastic hematopoiesis at
which CLL-1, CD44, and CD47 were aberrantly expressed and at which ALDH was downregu-
lated in MDS-EB and we showed that the myeloid markers CD13/CD33 were aberrantly
expressed on CMPs and MEPs in both low-risk and MDS-EB patients (Fig 6). Aberrant
expression at the most immature hematopoietic stem cell level could only be detected in the
case of CLL-1, establishing CLL-1 as a promising therapeutic target.
Supporting information
S1 Fig. Proportion of hematopoietic stem and progenitor cell compartments in MDS ver-
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cell; LMPP, lymphoid-primed multipotent progenitor cells; MEP, megakaryocytic erythroid
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